Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study = Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study

다국어 초록 (Multilingual Abstract)

Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients.
Methods: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12).
Results: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×10⁶ IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%).
Conclusions: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries. (Clin Mol Hepatol 2021;27:125-135)

참고문헌 (Reference)

• 1 Baatarkhuu O, "Viral hepatitis and liver diseases in Mongolia" 7 : 68-72, 2017
• 2 Chon YE, "The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B" 46 : 518-525, 2012
• 3 Lai CL, "Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong" 43 : 96-101, 2016
• 4 Tsuji K, "Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group" 53 : 1142-1150, 2018
• 5 Baatarkhuu O, "Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia:a population-based nationwide study" 28 : 1389-1395, 2008
• 6 Hye Won Lee, "Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response" 거트앤리버 소화기연관학회협의회 10 (10): 429-436, 2016
• 7 Zeuzem S, "NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome" 66 : 910-918, 2017
• 8 Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease" 149 : 649-659, 2015
• 9 Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection" 370 : 1889-1898, 2014
• 10 Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1infection" 370 : 1483-1493, 2014
• 11 AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection" 67 : 1477-1492, 2018
• 12 Zeng QL, "Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study" 66 : 1123-1129, 2017
• 13 Baatarkhuu O, "Epidemiology, genotype distribution, prognosis, control, and management of viral hepatitis B, C, D, and hepatocellular carcinoma in Mongolia" 8 : 57-62, 2018
• 14 European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018" 69 : 461-511, 2018
• 15 European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016" 66 : 153-194, 2017
• 16 Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection" 43 : 1317-1325, 2006
• 17 Jung KS, "Clinical applications of transient elastography" 18 : 163-173, 2012
• 18 Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection" 364 : 1195-1206, 2011
• 19 Omata M, "APASL consensus statements and recommendation on treatment of hepatitis C" 10 : 702-726, 2016
• 20 Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C" 38 : 518-526, 2003